BioTuesdays
Dresner Partners

Dresner Partners opens office in Florida

Dresner Partners has opened a new office in Fort Lauderdale, FL to be headed by Mitchell Stern, managing director and head of Dresner Partners’ healthcare practice.  Mr. Stern will also continue to spend a portion of...

Mateon Therapeutics

Mateon collaborates with US Oncology Research

US Oncology Research will participate in Mateon Therapeutics’ (NASDAQ:MATN) FOCUS clinical trial in platinum-resistant ovarian cancer. In a statement, Dr. William Schwieterman, president and CEO of Mateon, said US...

M Pharmaceutical

M Pharma posts successful pilot studies

M Pharmaceutical (OTCQB:MPHMF; CSE:MQ) announced findings from the third of three proprietary pilot studies related to the recently acquired Chelatexx technology, or the company’s C-103 project. The third study...

Vital Therapies

Vital Therapies updates Phase 3 trial

In a corporate update, Vital Therapies (NASDAQ:VTL) reported that 14 subjects have been enrolled at sites in the U.S. and EU in VTL-308, the company’s Phase 3 trial, designed to evaluate the ELAD System in...

Dipexium Pharmaceuticals

Dipexium receives Locilex patent in EU

Dipexium Pharmaceuticals (NASDAQ:DPRX) said that the European Patent Office has issued a new Locilex patent in the EU. The patent claims are directed to a novel formulation of Locilex, a topical antimicrobial peptide...

Tonix Pharmaceuticals Logo

Tonix Pharma AFFIRM trial fails

Tonix Pharmaceuticals Holding (NASDAQ:TNXP) said its Phase 3 AFFIRM study, designed to evaluate the safety and efficacy of TNX-102 SL in patients with fibromyalgia, did not achieve statistical significance in the...

ASLAN Pharmaceuticals

ASLAN Pharma in licensing pact with A*STAR

Closely-held ASLAN Pharmaceuticals has licensed a novel immuno-oncology antibody, targeting RON (Recepteur d’Origine Nantais), from Singapore’s Agency for Science, Technology and Research (A*STAR). RON is a receptor...

Mesoblast Logo

Mesoblast names Bill Burns as vice chairman

Mesoblast (NASDAQ:MESO; ASX:MSB) appointed William Burns, a director, as vice chairman. In this role, Mr. Burns, a former CEO of Roche Pharmaceuticals from 2001 to 2009, will focus his considerable pharmaceutical...

Valeant Pharmaceuticals

Valeant to commercialize Contrave in Canada

Valeant Canada, a subsidiary of Valeant Pharmaceuticals International (NYSE, TSX: VRX), will commercialize Orexigen Therapeutics’ (NASDAQ:OREX) Contrave (naltrexone HCl / bupropion HCl extended release) in Canada. Under...

ARIAD Pharmaceuticals

ARIAD completes NDA submission for brigatinib

ARIAD Pharmaceuticals (NASDAQ:ARIA) has completed a rolling NDA submission to the FDA for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib. ARIAD is seeking U.S. marketing approval of...

Regenicin

Regenicin gets orphan-drug status for NovaDerm

The FDA has granted orphan-drug status to Regenicin’s (OTC:RGIN) NovaDerm cultured skin substitute. In a statement, the company said it believes NovaDerm to be the only autologous cultured skin substitute prepared from...